Biotech Showcase
Join us virtually
January 10–12, 2022 &January 17–19, 2022

Myrtle Potter
CEO at Sumitovant


Myrtle Potter is CEO of Sumitovant Biopharma, Inc.  Sumitovant is a multi-billion-dollar, global biopharmaceutical company that develops novel medicines through a technology-first approach to drug discovery, development, and commercialization.  Sumitovant is the parent company of four wholly owned subsidiaries including Urovant, Enzyvant, Altavant, Spirovant, and one publicly listed, majority-owned subsidiary, Myovant.  Sumitovant companies secured four NDA approvals and one MAA  approval in 2021.

Previously, Myrtle served as Vant Operating Chair of Roivant Sciences where she oversaw nine biopharmaceutical companies with over thirty investigational drugs in eleven therapeutic areas and guided two of the companies through successful IPOs.  Prior to Roivant, Potter served as CEO of Myrtle Potter & Company, a healthcare advisory firm she started in 2005.

Potter served as President of Commercial Operations, and earlier, as COO and EVP of Genentech, where she led the company through nineteen of twenty consecutive quarters of record sales and earnings and launched seven novel therapies in five years.  Before Genentech, Myrtle was President of Bristol-Myers Squibb’s multi-billion-dollar U.S. Cardiovascular/Metabolics business.

Myrtle began her biopharmaceutical career at Merck where she started Astra Merck which, through a series of transactions, became a part of AstraZeneca PLC.  She is a graduate of the University of Chicago and serves on the boards of Myovant Sciences, Liberty Mutual Insurance Group, and Guardant Health.  

Agenda Sessions

  • The Biden Policy: Will its Impact on the Biopharma Sector be a Net Gain or Loss?